{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T17:14:14Z","timestamp":1758474854303,"version":"3.40.4"},"reference-count":34,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T00:00:00Z","timestamp":1741824000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019265","name":"Yuhan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.clinthera.2025.03.001","type":"journal-article","created":{"date-parts":[[2025,3,23]],"date-time":"2025-03-23T08:33:20Z","timestamp":1742718800000},"page":"436-444","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["A Phase III Randomized, Double-Blind, Active-Controlled, Multicenter Study on the Efficacy and Safety of Ezetimibe\/Atorvastatin\/Amlodipine Combination in Patients With Comorbid Primary Hypercholesterolemia and Essential Hypertension"],"prefix":"10.1016","volume":"47","author":[{"given":"Chan Joo","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji Yong","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seung Hwan","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinho","family":"Shin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jung Hyun","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eung Ju","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin-Oh","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jung-Hoon","family":"Sung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kye Hun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pil Hyung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Byung-Hee","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young Won","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seok-Min","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2025.03.001_bib0001","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/S0140-6736(20)30925-9","article-title":"Global burden of 369 diseases and injuries in 204 countries and territories, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"396","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2025.03.001_bib0002","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.amjcard.2006.01.079","article-title":"Prevalence, treatment, and control of combined hypertension and hypercholesterolemia in the United States","volume":"98","author":"Wong","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.clinthera.2025.03.001_bib0003","first-page":"3702","article-title":"Effect of elevated total cholesterol level and hypertension on the risk of fatal cardiovascular disease: a cohort study of Chinese steelworkers","volume":"124","author":"Yang","year":"2011","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.clinthera.2025.03.001_bib0004","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1001\/jama.290.7.891","article-title":"Major risk factors as antecedents of fatal and nonfatal coronary heart disease events","volume":"290","author":"Greenland","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2025.03.001_bib0005","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1016\/j.clinthera.2017.10.013","article-title":"A randomized, multicenter, double-blind, placebo-controlled study to evaluate the efficacy and the tolerability of a triple combination of amlodipine\/losartan\/rosuvastatin in patients with comorbid essential hypertension and hyperlipidemia","volume":"39","author":"Lee","year":"2017","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2025.03.001_bib0006","doi-asserted-by":"crossref","first-page":"237","DOI":"10.12997\/jla.2023.12.3.237","article-title":"Dyslipidemia fact sheet in South Korea, 2022","volume":"12","author":"Jin","year":"2023","journal-title":"J Lipid Atheroscler"},{"key":"10.1016\/j.clinthera.2025.03.001_bib0007","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s40256-023-00590-9","article-title":"A randomized, multicenter, double-blind, placebo-controlled study to evaluate the efficacy and safety of a quadruple combination of amlodipine, losartan, rosuvastatin, and ezetimibe in patients with concomitant essential hypertension and dyslipidemia","volume":"23","author":"Kim","year":"2023","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.clinthera.2025.03.001_bib0008","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.amjhyper.2004.10.017","article-title":"Dyslipidemic hypertension: distinctive features and cardiovascular risk in a prospective population-based study","volume":"18","author":"Onat","year":"2005","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.clinthera.2025.03.001_bib0009","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1111\/j.1524-6175.2007.07146.x","article-title":"Treatment of hypertension and dyslipidemia or their combination among US managed-care patients","volume":"9","author":"Dutro","year":"2007","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"10.1016\/j.clinthera.2025.03.001_bib0010","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3390\/metabo13010087","article-title":"Links between metabolic syndrome and hypertension: the relationship with the current antidiabetic drugs","volume":"13","author":"Stanciu","year":"2023","journal-title":"Metabolites"},{"year":"2024","series-title":"Atorvastatin","author":"McIver","key":"10.1016\/j.clinthera.2025.03.001_bib0011"},{"key":"10.1016\/j.clinthera.2025.03.001_bib0012","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1161\/01.CIR.0000068312.21969.C8","article-title":"Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial","volume":"107","author":"Ballantyne","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2025.03.001_bib0013","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s40256-016-0205-0","article-title":"Defining the place of ezetimibe\/atorvastatin in the management of hyperlipidemia","volume":"17","author":"Ferreira","year":"2017","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.clinthera.2025.03.001_bib0014","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1080\/14656566.2019.1594776","article-title":"Evaluating the efficacy and safety of atorvastatin + ezetimibe in a fixed-dose combination for the treatment of hypercholesterolemia","volume":"20","author":"Ma","year":"2019","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.clinthera.2025.03.001_bib0015","first-page":"47","article-title":"Fixed combination atorvastatin-ezetimibe (atozet\u00ae)]","volume":"71","author":"Scheen","year":"2016","journal-title":"Rev Med Liege"},{"key":"10.1016\/j.clinthera.2025.03.001_bib0016","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.028892","article-title":"Evolving management of low-density lipoprotein cholesterol: a personalized approach to preventing atherosclerotic cardiovascular disease across the risk continuum","volume":"12","author":"Wilkinson","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.clinthera.2025.03.001_bib0017","doi-asserted-by":"crossref","first-page":"ytae161","DOI":"10.1093\/ehjcr\/ytae161","article-title":"Drug-induced myocarditis precipitated by amlodipine overdose: a case report","volume":"8","author":"Skaria","year":"2024","journal-title":"Eur Heart J Case Rep"},{"author":"Food","key":"10.1016\/j.clinthera.2025.03.001_bib0018"},{"key":"10.1016\/j.clinthera.2025.03.001_bib0019","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1007\/s11906-007-0033-3","article-title":"Compliance and fixed-dose combination therapy","volume":"9","author":"Bangalore","year":"2007","journal-title":"Curr Hypertens Rep"},{"key":"10.1016\/j.clinthera.2025.03.001_bib0020","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/jch.14778","article-title":"Efficacy and safety of combination therapy with telmisartan, rosuvastatin, and ezetimibe in patients with dyslipidemia and hypertension: a randomized, double-blind, multicenter, therapeutic confirmatory, phase III clinical trial","volume":"26","author":"Lee","year":"2024","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"10.1016\/j.clinthera.2025.03.001_bib0021","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","article-title":"2016 ESC\/EAS guidelines for the management of dyslipidaemias","volume":"37","author":"Catapano","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clinthera.2025.03.001_bib0022","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1177\/0091270007307879","article-title":"A randomized, placebo-controlled trial to evaluate the efficacy, safety, and pharmacodynamic interaction of coadministered amlodipine and atorvastatin in 1660 patients with concomitant hypertension and dyslipidemia: the respond trial","volume":"47","author":"Preston","year":"2007","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2025.03.001_bib0023","doi-asserted-by":"crossref","first-page":"168","DOI":"10.3390\/diseases11040168","article-title":"Comparative efficacy and safety of statin monotherapy and statin plus ezetimibe combination in a real-world setting","volume":"11","author":"Ezhov","year":"2023","journal-title":"Diseases"},{"key":"10.1016\/j.clinthera.2025.03.001_bib0024","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/S0140-6736(18)31776-8","article-title":"Long-term mortality after blood pressure-lowering and lipid-lowering treatment in patients with hypertension in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Legacy study: 16-year follow-up results of a randomised factorial trial","volume":"392","author":"Gupta","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2025.03.001_bib0025","doi-asserted-by":"crossref","first-page":"618","DOI":"10.26599\/1671-5411.2023.09.007","article-title":"Chinese guideline for lipid management (2023): a new guideline rich in domestic elements for controlling dyslipidemia","volume":"20","author":"Li","year":"2023","journal-title":"J Geriatr Cardiol"},{"key":"10.1016\/j.clinthera.2025.03.001_bib0026","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1097\/HCO.0000000000000305","article-title":"IMPROVE-IT: what have we learned?","volume":"31","author":"Banach","year":"2016","journal-title":"Curr Opin Cardiol"},{"key":"10.1016\/j.clinthera.2025.03.001_bib0027","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/S0140-6736(22)00916-3","article-title":"Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial","volume":"400","author":"Kim","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2025.03.001_bib0028","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.3390\/jcm13051251","article-title":"Novel and emerging LDL-C lowering strategies: a new era of dyslipidemia management","volume":"13","author":"Agnello","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.clinthera.2025.03.001_bib0029","doi-asserted-by":"crossref","first-page":"7432","DOI":"10.3390\/jcm12237432","article-title":"Evolution of more aggressive LDL-cholesterol targets and therapies for cardiovascular disease prevention","volume":"12","author":"Jones","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.clinthera.2025.03.001_bib0030","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/j.jacc.2022.07.006","article-title":"2022 ACC expert consensus decision pathway on the role of nonstatin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"80","author":"Committee","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.clinthera.2025.03.001_bib0031","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1161\/01.CIR.0000018744.58460.62","article-title":"Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia","volume":"105","author":"Gagn\u00e9","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2025.03.001_bib0032","first-page":"377","article-title":"Fixed combination of amlodipine and atorvastatin in cardiovascular risk management: patient perspectives","volume":"5","author":"Devabhaktuni","year":"2009","journal-title":"Vasc Health Risk Manag"},{"key":"10.1016\/j.clinthera.2025.03.001_bib0033","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.2147\/DDDT.S165171","article-title":"Pharmacokinetic interaction between fimasartan and atorvastatin in healthy male volunteers","volume":"12","author":"Choi","year":"2018","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.clinthera.2025.03.001_bib0034","doi-asserted-by":"crossref","first-page":"202","DOI":"10.12793\/tcp.2017.25.4.202","article-title":"Pharmacokinetic drug interaction between atorvastatin and ezetimibe in healthy Korean volunteers","volume":"25","author":"Park","year":"2017","journal-title":"Transl Clin Pharmacol"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291825000748?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291825000748?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T13:37:45Z","timestamp":1746452265000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291825000748"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":34,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S0149291825000748"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2025.03.001","relation":{},"ISSN":["0149-2918"],"issn-type":[{"type":"print","value":"0149-2918"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Phase III Randomized, Double-Blind, Active-Controlled, Multicenter Study on the Efficacy and Safety of Ezetimibe\/Atorvastatin\/Amlodipine Combination in Patients With Comorbid Primary Hypercholesterolemia and Essential Hypertension","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2025.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}